significantly shorter in the patients who received a reduced dose of MTX (median, 4.5 vs 13.0 days; P = 0.013). In conclusion, GVHD prophylaxis with a reduced dose of MTX was associated with earlier engraftment and earlier recovery from mucositis in comparison to a standard dose of MTX, without affecting the incidence of GVHD.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used as curative treatment for various hematologic malignancies, bone marrow failure syndromes, and congenital immunodeficiencies. Graft-vs-host disease (GVHD) is one of the major complications after allogeneic HSCT [1] [2] [3] . The standard GVHD prophylaxis regimen is a combination of methotrexate (MTX) and a calcineurin inhibitor, such as cyclosporine A (CSA) or tacrolimus (TAC) [4] [5] [6] . Previous randomized controlled trials have suggested that the use of TAC and MTX reduces the incidence of acute GVHD in comparison to CSA and MTX, whereas no differences were observed in the incidence of chronic GVHD or survival [4, 5, 7] . The dose and schedule of MTX in GVHD prophylaxis differs between institutes. The original regimen of short-course MTX for GVHD prophylaxis was 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11 [8, 9] . MTX can be omitted or the dosage can be reduced on day +11 (10 mg/m 2 on day +1 and 7 mg/m 2 on days +3, +6 and +11) to mitigate the toxicities of MTX, which include mucositis and delayed engraftment [10] [11] [12] [13] [14] . However, the impact of modifying the dose of MTX is controversial [10, 11, 15, 16] . Furthermore, fewer studies have Abstract Allogeneic hematopoietic stem cell transplantation is a curable treatment for hematological diseases. Graftversus-host disease (GVHD) causes morbidity and mortality after HSCT. Methotrexate (MTX) is used for GVHD prophylaxis, but its appropriate dose remains unclear. In the present study, we compared the efficacy and toxicity of 15-10-10 MTX (day +1: 15 mg/m 2 ; days +3 and +6: 10 mg/m 2 ) with 10-7-7 MTX (day +1: 10 mg/m 2 ; day +3 and +6: 7 mg/m 2 ) in combination with tacrolimus. The cumulative incidence rates of grades II-IV acute GVHD, grades III-IV acute GVHD and chronic GVHD in the 15-10-10 MTX and 10-7-7 MTX groups did not differ to a statistically significant extent. The median time for neutrophil engraftment in the 15-10-10 MTX group was 16 days (range, 11-31 days), while that in the 10-7-7 group was 15 days (range, 12-19 days) (P = 0.024). Moreover, the median time for platelet recovery was significantly shorter in the 10-7-7 MTX group (22 days; range, 13-49 days) than that in the 15-10-10 MTX group (27 days; range, 9-405 days) (P = 0.027). The duration of oral mucositis was Electronic supplementary material The online version of this article (doi:10.1007/s12185-016-1996-0) contains supplementary material, which is available to authorized users. investigated the optimal doses of MTX in combination with TAC in comparison to MTX with CSA. In the present study, we retrospectively compared the efficacy and the incidence of toxicities with two different doses of MTX in combination with TAC as a prophylactic treatment against GVHD after allogeneic HSCT.
Patients and methods

Patients
Among the 208 consecutive patients who received HSCT in our institution between January 2010 and March 2015, the results of 76 patients who underwent HSCT with TAC plus short-course MTX were analyzed. The study was approved by the institutional review board of Hokkaido University Hospital.
GVHD prophylaxis
TAC was intravenously administered by continuous infusion from day −1 to maintain a target blood level of TAC at 10-15 ng/ml. At ~1 month after HSCT, it was changed to an oral form to maintain a trough blood level of TAC at 5-10 ng/ml. The blood levels of TAC were measured at least twice a week. The doses of MTX were as followed: 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3 and +6 (15-10-10 MTX) or 10 mg/m 2 on day +1 and 7 mg/m 2 on days +3 and +6 (10-7-7 MTX). The dose of MTX was selected according to the discretion of each physician. Patients who received anti-thymocyte globulin for GVHD prophylaxis were excluded from the analysis.
Supportive treatment
Patients received granulocyte colony-stimulating factor (G-CSF) from 5 days after HSCT until the time of neutrophil engraftment. Cytomegalovirus (CMV) reactivation was monitored at least once a week. When CMV reactivation was detected, valganciclovir or ganciclovir was administered as a pre-emptive therapy. Acyclovir and sulfamethoxazole/trimethoprim were administered to prevent herpes simplex virus/varicella zoster virus and Pneumocystis jirovecii, respectively.
Engraftment
The day of engraftment was defined as the first of 3 successive days after HSCT in which the neutrophil counts was >0.5 × 10 9 /L. The day of platelet recovery was defined as the first of 7 successive days in which the platelet count was >20 × 10 9 /L without platelet transfusion.
The evaluation of oral mucositis
Oral mucositis was evaluated daily and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. Briefly, Grade 1 denotes erythema of the mucosa. Grades 2 and 3 indicate patchy and confluent ulcerations or pseudomembranes, respectively. Grade 4 indicates tissue necrosis and significant spontaneous bleeding. Severe oral mucositis was defined as Grade 3-4 oral mucositis.
The evaluation of GVHD
Acute and chronic GVHD were graded according to the consensus criteria [17, 18] .
Statistical analysis
All statistical analyses were performed using the EZR software program (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [19] . P values of <0.05 were considered to indicate statistical significance. The cumulative incidence rates of GVHD and neutrophil engraftment and platelet recovery were calculated using the Gray's test and compared using a log-rank test. In these analyses, death or relapse were considered as competing events. Univariate analyses were performed using the χ 2 -test and Fisher's exact test. Factors with P values of <0.20 in the univariate analyses were included in a multivariate analysis. Stepwise multivariate logistic regression models were used to analyze the influence of selected variables on the risk of oral mucositis of over 14 days in duration.
Results
Patient characteristics
The patient characteristics are shown in Table 1 . Among the 76 patients who underwent HSCT with TAC plus MTX, 60 patients received 15-10-10 MTX and 16 patients received 10-7-7 MTX. With the exception of age, patient characteristics (including gender, disease, disease status, intensity of conditioning, graft type, degree of HLA matching, and sex) did not differ to a statistically significant extent between the two groups. The median age of the 10-7-7 MTX group was significantly higher than that of the 15-10-10 MTX group.
GVHD
The cumulative incidences rates of grades II-IV and III-IV acute GVHD in the 15-10-10 MTX and 10-7-7 MTX groups (grades II-IV: 35.0 vs 18.8 % (P = 0.36); grades III-IV: 11.7 vs 6.3 % (P = 1.0), respectively) did not differ to a statistically significant extent ( Fig. 1 ; Table 2 ). The median onset of acute GVHD was 30 days after transplantation (range, 11-96 days). The cumulative incidence of chronic GVHD did not differ between the two groups (31.7 vs 25.0 %; P = 0.76). Moreover, the cumulative incidences of acute and chronic GVHD were not significant differences between each graft type and HLA matching group in two groups (data not shown).
Overall survival and non-relapse mortality
Overall survival and non-relapse mortality (NRM) in the 15-10-10 MTX and 10-7-7 MTX groups (P = 0.70 and P = 0.97, respectively) did not differ to a statistically significant extent (Fig. 1) . Furthermore, early NRM on day +28 did not differ between the two groups (P = 0.46).
Neutrophil engraftment and infection complications
Graft failure was only documented in three patients (3.9 %) in the 15-10-10 MTX group. The median time for neutrophil engraftment was significantly shorter in the 10-7-7 MTX group (15 days; range, 12-19 days) than in the 15-10-10 MTX group (16 days; range, 11-31 days) (P = 0.024) (Fig. 2a, b) . The median time for neutrophil engraftment after HLA-matched bone marrow transplantation (BMT) was also significantly shorter in the 10-7-7 MTX group (14.5 days; range, 12-16 days) than in the 15-10-10 MTX group (15.5 days; range, 12-27 days) (P = 0.0046) (Fig. 2c,  d ). In contrast, there as no statistical difference between the two groups with respect to infectious complications before neutrophil engraftment (P = 1.0). The median time for neutrophil engraftment in the patients who received HLAmatched HSCT was not significantly different from that of the patients who received HLA-mismatched HSCT (data not shown).
Platelet recovery
The median time for platelet recovery was significantly shorter in the 10-7-7 MTX group (22 days; range, 13-49 days) than that in the 15-10-10 MTX group (27 days; range, 9-405 days) (P = 0.027) (Fig. 2e) .
Oral mucositis
Severe oral mucositis was observed in 18 patients (23.7 %) of the overall population. The incidence of severe oral mucositis in the 10-7-7 MTX group did not differ from that in the 15-10-10 MTX group (12.5 vs 26.7 %; P = 0.33). Interestingly, the duration of oral mucositis was significantly shorter in the 10-7-7 MTX group (median 4.5 days; range, 0-16 days) than that in the 15-10-10 MTX group (median 13.0 days; range, 0-53 days) (P = 0.013) ( Table 2) .
The univariate and multivariate analyses of the risk factors for prolonged severe mucositis
The duration of oral mucositis was modestly correlated with the time to neutrophil engraftment (Supplementary Figure 1) . A univariate analysis demonstrated that 15-10-10 MTX and severe oral mucositis were risk factors for prolonged oral mucositis (>14 days) ( Table 3) . A multivariate analysis confirmed that the existence of severe oral mucositis [OR, 18.0; 95 % confidence interval (CI), 3.99-81.05; P < 0.001] and 15-10-10 MTX were risks for prolonged oral mucositis (OR, 0.094; 95 % CI, 0.0090-0.98; P = 0.048) ( Table 4) .
Discussion
Although it has been well acknowledged that conditioning therapy (such as high-dose chemotherapy and TBI) causes severe mucositis, MTX (which is used for GVHD prophylaxis) also contributes to the progression of mucositis and possibly delayed engraftment [20] . Several strategies have been tested to reduce the incidence of MTX-related toxicities. First, the dose and duration of MTX can be reduced. A meta-analysis comparing the administration of three and four doses of MTX for GVHD prophylaxis showed that administration of MTX on day +11 was associated with an increased incidence of leukemic relapse, but there was no significant difference in the risk of acute GVHD or overall survival in patients who received three and four doses of MTX after BMT and the incidence of oral mucositis was not compared [15] . Second, MTX can be replaced by mycophenolate mofetil (MMF), which reduces the incidence of mucositis without inhibiting neutrophil engraftment. However, the advantages of MMF were not obvious in HSCT in patients who received a myeloablative regimen [21] . A meta-analysis showed that the incidence of grades III-IV acute GVHD in patients who received a GVHD prophylaxis regimen that contained MMF was higher than that in patients who received a regimen containing MTX. MMF is associated with a decreased risk of oral mucositis [22] , and may lead to reduced narcotics use and a shorter hospital stay [23] . Lastly, the administration of folinic acid may reduce the incidence of oral mucositis [24] . Several studies have reported that the systemic administration of folinic acid, which is routinely used to mitigate MTX toxicities, potentially reduces the incidence of severe oral mucositis after HSCT [25] [26] [27] . The incidence of GVHD in Japanese patients is lower than that in Caucasians [28, 29] , possibly due to the more homogenous genetic background of the Japanese population [30] . In many Japanese institutes, day +11 MTX is usually omitted in HLA-matched transplantation from a sibling donor [31] [32] [33] , whereas four doses are standard in Western countries [15] . To our knowledge, this is the first study to compare 10-7-7 MTX and 15-10-10 MTX in combination with TAC for GVHD prophylaxis. We found that reduced doses of MTX (10-7-7 MTX) resulted in the earlier engraftment of neutrophils and platelets, and the mitigation of oral mucositis, without increasing the incidence of acute or chronic GVHD. The shorter duration of severe mucositis may be associated with a reduced risk of infection [34] . However, the present study was retrospective in nature and involved a small number of patients. Further study is therefore required to confirm our results in a prospective study. It should be noted that there is great inter-individual variability in MTX metabolism, which may affect the outcome of HSCT using MTX [35, 36] . The cumulative incidence rates of acute and chronic GVHD in the 15-10-10 MTX and 10-7-7 MTX groups, just limited to each graft type and HLA match groups, did not differ to a significant extent in our study. In conclusion, our analysis indicated the superiority and safety of the 10-7-7 MTX for GVHD prophylaxis in Japanese patients, regardless of HLA disparity. 
